Determination of tumor response to treatment in neuro-oncology is challenging, particularly
when antiangiogenic agents are considered. Nontumoral factors (eg, blood-brain barrier …

Response criteria for paediatric high-grade glioma vary historically and across different
cooperative groups. The Response Assessment in Neuro-Oncology working group …

Since 1990, the primary criteria used for assessing response to therapy in high-grade
gliomas were those developed by Macdonald and colleagues, which incorporated 2 …

Paediatric low-grade gliomas (also known as pLGG) are the most common type of CNS
tumours in children. In general, paediatric low-grade gliomas show clinical and biological …

BACKGROUND AND PURPOSE: HERBY was a Phase II multicenter trial setup to establish
the efficacy and safety of adding bevacizumab to radiation therapy and temozolomide in …

The introduction of antiangiogenic therapies for the treatment of malignant glioma and the
effect of these agents on standard imaging studies were the stimuli for forming a small group …

Abstract Development of novel therapies for CNS tumors requires reliable assessment of
response and progression. This requirement has been particularly challenging in neuro …

Pediatric brain tumors differ from those in adults by location, phenotype and genotype. In
addition, they show dissimilar imaging characteristics before and after treatment. While adult …

Opinion Statement Treatment options for most nervous system tumors remain limited and
patients are often confronted with significant morbidity and reduced life expectancy …

Criteria for new drug approval include demonstration of efficacy. In neuro‐oncology, this is
determined radiographically utilizing tumor measurements on MRI scans. Limitations of this …